About Beth Seidenberg
Beth Seidenberg is a director and 10% owner at Latigo Biotherapeutics.
Beth Seidenberg reports to the SEC as a director or major shareholder of 11 public companies, including Sagimet Biosciences (SGMT), Kyverna Therapeutics (KYTX) and Vera Therapeutics (VERA).
Beth Seidenberg first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Beth Seidenberg in the role, so the role may have started earlier or lasted longer.
SI
Sagimet Biosciences Inc.
Director
2023 – 2026 · Public company (SGMT)
KI
VI
Vera Therapeutics, Inc.
Director
2021 – 2026 · Public company (VERA)
AI
Acelyrin, Inc.
Director and 10% owner
2023 – 2025 · Public company (SLRN)
PI
Progyny, Inc.
Director
2019 – 2024 · Public company (PGNY)
AI
Atara Biotherapeutics, Inc.
Director and 10% owner
2014 – 2023 · Public company (ATRA)
EI
Epizyme, Inc.
Director and 10% owner
2013 – 2019 · Public company (EPZM)
TI
Tesaro, Inc.
Director
2012 – 2019 · Public company (TSRO)
AI
ARMO BioSciences, Inc.
Director and 10% owner
2018 · Public company (ARMO)
BI
Biocryst Pharmaceuticals Inc.
Director
2006 – 2010 · Public company (BCRX)
Key Colleagues at Startups
The people Beth Seidenberg works with at each company, as listed on that company's latest Form D.
Latigo Biotherapeutics, Inc. · Form D, Feb 13, 2025
NS
Nancy Stagliano
Director
NF
Nima Farzan
Executive officer and director
JT
Jim Tananbaum
Director
DP
Deborah Palestrant
Director
KR
Kevin Raidy
Director
TL
Tim Lugo
Chief Financial Officer
TW
Tim Walbert
Director